DPP4 and type 2 diabetes mellitus: In summary, this real-world cohort study suggests that among patients with type 2 diabetes and bipolar disorder, SGLT-2 inhibitor therapy is associated with a lower risk of suicide-related events compared to DPP-4 inhibitor therapy.